<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02707575</url>
  </required_header>
  <id_info>
    <org_study_id>3-2015-0304</org_study_id>
    <nct_id>NCT02707575</nct_id>
  </id_info>
  <brief_title>Cytokeratin 8 Level in Age-related Macular Degeneration</brief_title>
  <official_title>Cytokeratin 8 Level in Aqueous Humor, as a Prognostic Factor for Visual and Anatomical Outcomes After Ranibizumab (Lucentis) in Neovascular Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gangnam Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Konkuk University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gangnam Severance Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will evaluate the concentrations of cytokeratin 8 in aqueous humor in eyes&#xD;
      with exudative age-related macular degeneration (AMD) before therapy with intravitreal&#xD;
      Ranibizumab, and identify associations with visual and anatomical outcome after treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this non-randomized, and open-label study, the investigators will prospectively evaluate&#xD;
      58 patients with treatment naive exudative age-related macular degeneration (AMD) who receive&#xD;
      intravitreal ranibizumab injection. A mean volume of 0.1 ml of aqueous humor samples will be&#xD;
      taken each time an intravitreal injection is indicated and performed. Cytokeratin 8 level in&#xD;
      aqueous humor will be evaluated, and associations of baseline cytokeratin 8 level and visual&#xD;
      (the best corrected visual acuity change) and anatomical (optical coherence tomography&#xD;
      parameters) after Ranibizumab injection will be investigated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 26, 2016</start_date>
  <completion_date type="Actual">April 23, 2018</completion_date>
  <primary_completion_date type="Actual">March 12, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The changes in the Logarithm of the Minimum Angle of Resolution (LogMAR) visual acuity</measure>
    <time_frame>From baseline to one month after three monthly consecutive ranibizumab injection</time_frame>
    <description>The changes in the Logarithm of the Minimum Angle of Resolution (LogMAR) visual acuity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The presence of intra/subretinal fluid on Spectral domain (SD)- Optical Coherence Tomography (OCT)</measure>
    <time_frame>From baseline to one month after three monthly consecutive ranibizumab injection</time_frame>
    <description>The presence of intra/subretinal fluid on Spectral domain (SD)- Optical Coherence Tomography (OCT)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">58</enrollment>
  <condition>Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Ranibizumab</arm_group_label>
    <description>Intravitreal Ranibizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>Three monthly consecutive injections of 0.5-mg ranibizumab will be performed. Aqueous humor samples will be taken each time an intravitreal injection in indicated and performed.</description>
    <arm_group_label>Ranibizumab</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Aqueous humor&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Included patient is required to be least 50 years of age with newly diagnosed exudative&#xD;
        age-related macular degeneration, with a recent onset of disease.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Treatment-naive neovascular AMD patients requiring intravitreal injection of&#xD;
             Ranibizumab&#xD;
&#xD;
          2. A recent onset of disease confirmed by history and clinical findings.&#xD;
&#xD;
          3. Patient is required to be least 50 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Myopia with a refractive error &gt;-3.0 diopters or evidence of pathologic myopia&#xD;
             (pre-operative refractive data were used to assess pseudophakic eyes)&#xD;
&#xD;
          2. Any history of vitrectomy, anti-VEGF therapy, or photodynamic therapy (PDT)&#xD;
&#xD;
          3. History of cataract surgery within 3 months prior to presentation&#xD;
&#xD;
          4. Evidence of end-stage AMD such as subfoveal fibrosis or atrophy&#xD;
&#xD;
          5. Evidence of other retinal diseases including central serous chorioretinopathy and&#xD;
             other neovascularmaculopathies; glaucoma; poor imaging data caused by media opacity;&#xD;
             or unstable fixation&#xD;
&#xD;
          6. Patients with uncontrolled systemic diseases, use of immunosuppressive drugs, or&#xD;
             malignant tumors of any location&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suk Ho Byeon, MD. Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor. Yonsei University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inje University Ilsan Paik Hospital</name>
      <address>
        <city>Goyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>March 3, 2016</study_first_submitted>
  <study_first_submitted_qc>March 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2016</study_first_posted>
  <last_update_submitted>December 5, 2020</last_update_submitted>
  <last_update_submitted_qc>December 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gangnam Severance Hospital</investigator_affiliation>
    <investigator_full_name>Suk Ho Byeon</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Keratin</keyword>
  <keyword>Ranibizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 4, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT02707575/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

